Biogen’s Litifilimab Milestone Puts Spotlight On Valuation And Growth Prospects

Biogen's investigational drug litifilimab has received FDA Breakthrough Therapy Designation for treating cutaneous lupus ...

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...
Seeking Alpha

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ThecaFlex DRx™ has ...
Seeking Alpha

Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra

Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar developed by Biogen (NASDAQ:BIIB) as an intravenous therapy targeting Roche’s ...
The Business Journals

Biogen Latest News

December 25, 2025, 8:37 PM ESTHealth Care November 30, 2025, 6:53 PM ESTTechnology November 24, 2025, 2:02 PM ESTHealth Care November 19, 2025, 9:57 AM ESTHealth Care November 13, 2025, 4:05 PM ...
Insider Monkey

Biogen (BIIB) Price Target Hiked to $130 at UBS amid Leqembi Development

Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated a ‘Neutral’ rating on the stock and raised the price target to $130 from ...